
Nanobiotix SA (NBTX) Stock Forecast & Price Target
Nanobiotix SA (NBTX) Analyst Ratings
Bulls say
Nanobiotix is a promising company with a strong focus on revolutionizing medicine through their proprietary nanotechnology. The company has a large market opportunity with their Nanoradioenhancer platform, Nanoprimer platform, and Neurological disease platform. Their lead product candidate, JNJ-1900, is showing promising results in multiple solid tumor indications and has the support of a global pharmaceutical partner. With upcoming pivotal results and partnership updates, there is significant potential for upside in this stock.
Bears say
Nanobiotix is facing challenges with logistics in practice, has high execution and financial risk, as well as the possibility of dilutive financing. The company also relies heavily on milestones for revenue and faces competition in the market. With a current valuation of $36 per ADR based on a DCF analysis, there is potential for downside risks, including disappointing product launches and clinical trial failures. Additional risks include legal issues and government regulations.
This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.
Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction
Start investing in Nanobiotix SA (NBTX)
Order type
Buy in
Order amount
Est. shares
0 shares